GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Misonix Inc (NAS:MSON) » Definitions » Altman Z-Score

Misonix (Misonix) Altman Z-Score : 4.39 (As of May. 05, 2024)


View and export this data going back to 2019. Start your Free Trial

What is Misonix Altman Z-Score?

The Altman Z-Score is a model designed to predict the likelihood of a company going bankrupt within the next two years. Created by American finance professor Edward Altman in 1968, the model is specifically designed for publicly traded manufacturing companies with assets greater than $1 million.

Good Sign:

Altman Z-score of 4.4 is strong.

Misonix has a Altman Z-Score of 4.39, indicating it is in Safe Zones. This implies the Altman Z-Score is strong.

The zones of discrimination were as such:

When Altman Z-Score <= 1.8, it is in Distress Zones.
When Altman Z-Score >= 3, it is in Safe Zones.
When Altman Z-Score is between 1.8 and 3, it is in Grey Zones.

The historical rank and industry rank for Misonix's Altman Z-Score or its related term are showing as below:

MSON' s Altman Z-Score Range Over the Past 10 Years
Min: 0.59   Med: 4.55   Max: 18.02
Current: 4.4

During the past 13 years, Misonix's highest Altman Z-Score was 18.02. The lowest was 0.59. And the median was 4.55.


Misonix Altman Z-Score Historical Data

The historical data trend for Misonix's Altman Z-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Misonix Altman Z-Score Chart

Misonix Annual Data
Trend Jun12 Jun13 Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21
Altman Z-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 11.04 16.15 17.85 2.48 3.68

Misonix Quarterly Data
Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21
Altman Z-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.48 2.03 2.36 3.48 3.68

Competitive Comparison of Misonix's Altman Z-Score

For the Medical Devices subindustry, Misonix's Altman Z-Score, along with its competitors' market caps and Altman Z-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Misonix's Altman Z-Score Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Misonix's Altman Z-Score distribution charts can be found below:

* The bar in red indicates where Misonix's Altman Z-Score falls into.



Misonix Altman Z-Score Calculation

Altman Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.

Misonix's Altman Z-Score for today is calculated with this formula:

Z=1.2*X1+1.4*X2+3.3*X3+0.6*X4+1.0*X5
=1.2*0.1839+1.4*-0.2705+3.3*-0.0539+0.6*7.2644+1.0*0.3722
=4.39

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency. GuruFocus does not calculate Altman Z-Score when X4 or X5 value is 0.

Trailing Twelve Months (TTM) ended in Jun. 2021:
Total Assets was $198.86 Mil.
Total Current Assets was $59.27 Mil.
Total Current Liabilities was $22.69 Mil.
Retained Earnings was $-53.79 Mil.
Pre-Tax Income was -4.341 + -3.757 + -1.265 + -4.979 = $-14.34 Mil.
Interest Expense was -0.87 + -0.866 + -0.949 + -0.934 = $-3.62 Mil.
Revenue was 19.685 + 18.347 + 18.256 + 17.735 = $74.02 Mil.
Market Cap (Today) was $462.46 Mil.
Total Liabilities was $63.66 Mil.

* Note that for stock reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data.

X1=Working Capital/Total Assets
=(Total Current Assets - Total Current Liabilities)/Total Assets
=(59.267 - 22.692)/198.86
=0.1839

X2=Retained Earnings/Total Assets
=-53.785/198.86
=-0.2705

X3=Earnings Before Interest and Taxes/Total Assets
=(Pre-Tax Income - Interest Expense)/Total Assets
=(-14.342 - -3.619)/198.86
=-0.0539

X4=Market Value Equity/Book Value of Total Liabilities
=Market Cap/Total Liabilities
=462.461/63.661
=7.2644

X5=Revenue/Total Assets
=74.023/198.86
=0.3722

The zones of discrimination were as such:

Distress Zones - 1.81 < Grey Zones < 2.99 - Safe Zones

Misonix has a Altman Z-Score of 4.39 indicating it is in Safe Zones.

Study by Altman found that companies that are in Distress Zone have more than 80% of chances of bankruptcy in two years.


Misonix  (NAS:MSON) Altman Z-Score Explanation

X1: The Working Capital/Total Assets (WC/TA) ratio is a measure of the net liquid assets of the firm relative to the total capitalization. Working capital is defined as the difference between current assets and current liabilities. Ordinarily, a firm experiencing consistent operating losses will have shrinking current assets in relation to total assets. Altman found this one proved to be the most valuable liquidity ratio comparing with the current ratio and the quick ratio. This is however the least significant of the five factors.

X2: Retained Earnings/Total Assets: the RE/TA ratio measures the leverage of a firm. Retained earnings is the account which reports the total amount of reinvested earnings and/or losses of a firm over its entire life. Those firms with high RE, relative to TA, have financed their assets through retention of profits and have not utilized as much debt.

X3, Earnings Before Interest and Taxes/Total Assets (EBIT/TA): This ratio is a measure of the true productivity of the firm's assets, independent of any tax or leverage factors. Since a firm's ultimate existence is based on the earning power of its assets, this ratio appears to be particularly appropriate for studies dealing with corporate failure. This ratio continually outperforms other profitability measures, including cash flow.

X4, Market Value of Equity/Book Value of Total Liabilities (MVE/TL): The measure shows how much the firm's assets can decline in value (measured by market value of equity plus debt) before the liabilities exceed the assets and the firm becomes insolvent.

X5, Revenue/Total Assets (S/TA): The capital-turnover ratio is a standard financial ratio illustrating the sales generating ability of the firm's assets.

Read more about Altman Z-Score and the original research.


Be Aware

Altman Z-Score does not apply to financial companies.


Misonix Altman Z-Score Related Terms

Thank you for viewing the detailed overview of Misonix's Altman Z-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Misonix (Misonix) Business Description

Traded in Other Exchanges
N/A
Address
1938 New Highway, Farmingdale, NY, USA, 11735
Misonix Inc is a medical devices company. It designs, manufactures, markets, and sells invasive surgical ultrasonic medical devices. The company's products enhance clinical outcomes and provide value to the overall healthcare system. It has developed products such as BoneScalpel, NeXus, Sequel, SonaStar, SonicOne, Theragenesis, TheraSkin, and Therion. These products are used for precise bone sculpting, removal of soft and hard tumors, tissue debridement, primarily in the areas of neurosurgery, orthopedic surgery, plastic surgery, wound care, and maxillo-facial surgery. The company generates revenue from various regions that include the United States, the United Kingdom, the European Economic Area, Asia and the Asia Pacific, and South America.
Executives
Paul A Laviolette director ONE BOSTON PLACE, 201 WASHINGTON STREET, SUITE 3900, BOSTON MA 02108
Sharon W Klugewicz officer: Chief Operating Officer 3661 HORSEBLOCK ROAD, MEDFORD NY 11763
Thomas M Patton director C/O OSTEOTCH INC., 51 JAMES WAY, EATONTOWN NJ 07724
Joseph P Dwyer officer: Chief Financial Officer 3 CORDWOOD COURT, E. NORTHPORT NY 11731
Gwendolyn A Watanabe director C/O SARATOGA VENTURES, 210 ALMENDRA AVENUE, LOS GATOS CA 95030
Linwood A. Staub officer: Sr. VP Wound 8023 VANTAGE DRIVE SAN ANTONIO TX 78230
Stavros G. Vizirgianakis director, officer: CEO 1/16-18 TENNYSON ST., WILLIAMSTOWN NORTH, VICTORIA CA 3016
Robert S Ludecker officer: SVP Sales - Surgical 4 WILDBRIAR COURT MOUNT SINAI NY 11766
Allan Richard Staley officer: President C/O SOLSYS MEDICAL, LLC 600 THIMBLE SHOALS BLVD., SUITE 200 NEWPORT NEWS VA 23606
Michael Koby director C/O 1315 CAPITAL 2929 WALNUT STREET, SUITE 1240 PHILADELPHIA PA 19104
1315 Capital Management, Llc 10 percent owner 2929 WALNUT STREET SUITE 1240 PHILADELPHIA PA 19104
Sv Life Sciences Fund Vi (gp), L.p. 10 percent owner ONE BOSTON PLACE, 201 WASHINGTON STREET, SUITE 3900, BOSTON MA 02108
Svlsf Vi, Llc 10 percent owner ONE BOSTON PLACE, 201 WASHINGTON STREET, SUITE 3900, BOSTON MA 02108
Sv Life Sciences Fund Vi Strategic Partners, L.p. 10 percent owner C/O SV LIFE SCIENCES ADVISERS, LLC, ONE BOSTON PLACE, SUITE 3900, BOSTON MA 02108
1315 Capital, L.p. 10 percent owner 3020 MARKET STREET, SUITE 104 PHILADELPHIA PA 19104